Background
Methods
Subject characteristics
Peripheral blood puncture
Biomarkers measurements in serum
Pulmonary function tests
Statistical analysis
Results
Subject demographic functional and blood characteristics
Healthy subjects n = 55 | Untreated IPF n = 24 | Treated IPF n = 26 | |
---|---|---|---|
Age, yrs | 60 (8) | 74 (9)*** | 68 (9)*** |
Gender (M/F) | 28/27 | 19/5 | 16/3 |
Height, cm | 170 (8) | 168 (10) | 170 (9) |
Weight, Kg | 75 (12) | 74 (16) | 78 (11) |
BMI, Kg/m2 | 26 (3) | 26 (4) | 27 (3) |
Smokers (NS/FS/S) | 23/22/6 | 3/8/6 | (6/19/0) |
Leucocytes x103/μl | 7.00 (5.39) | 8.35 (2.35)* | 8.42 (2.91)** |
Neutrophils (Cell/μl) | 3450 (1025) | 5614 (2113)*** | 5960 (3053)*** |
Lymphocytes (Cell/μl) | 2085 (620) | 1676 (825)* | 1786 (643) |
Monocytes (Cell/μl) | 486 (160) | 698 (325)** | 725 (218)*** |
Eosinophils (Cell/μl) | 173 (125) | 314 (266)** | 214 (128) |
Basophils (Cell/μl) | 33 (17) | 55 (67) | 94 (187) |
Fibrinogen (g/l) | 3 (0.80) | a4 (1.40)*** | nd |
CRP (mg/l) | 1.9 (2.89) | a30 (37.89)*** | nd |
FEV1 post-BD, %pred. | 105 (12) | 75 (14)*** | 67 (13)*** |
FVC post-BD, %pred. | 111 (16) | 73 (14)*** | 66 (16)*** |
TLC, %pred. | nd | 71 (19) | 68 (15) |
DLCO %pred. | nd | 37 (11) | 38 (13) |
KCO %pred. | nd | 63 (16) | 70 (20) |
Treatment (pirfenidone/nintedanib) | 0/0 | 0/0 | 17/9 |
Pirfenidone (duration of treatment -Month) | nd | nd | 9.9 (7.4) |
Nintedanib (duration of treatment -Month) | nd | nd | 14.3 (15.8) |
Serum growth factors
Healthy subjects | Untreated IPF | Treated IPF | |
---|---|---|---|
IGF-1 (ng/ml) | 31 (7–67) | 20 (9–102)* | 25 (11–57) |
IGF-2 (ng/ml) | 710 (401–2232) | 590 (210–1027)* | 586 (282–920)** |
IGFBP-1 (ng/ml) | 11 (0–180) | 22 (4–110)* | 9 (1–107) |
IGFBP-2 (ng/ml) | 94 (34–211) | 206 (113–317)*** | 153 (32–291)** ° |
IGFBP-3 (ng/ml) | 2132 (1207–4059) | 1536 (534–2556)* | 2032 (893–3505) |
Molar ratio IGF-1 : IGFBP-1 | 12 (1–314) | 3,5 (0,3–36,3)* | 9 (1–152) |
Molar ratio IGF-1 : IGFBP-2 | 1,8 (0,2–6,2) | 0,4 (0–4,3)*** | 0,7 (0,3–5,2)* |
Molar ratio IGF-1 : IGFBP-3 | 0,06 (0,02–0,12) | 0,05 (0,03–0,25) | 0,05 (0,03–0,1) |
Molar ratio IGF-2 : IGFBP-1 | 247 (20–6735) | 110 (11–769)* | 259 (20–2429) |
Molar ratio IGF-2 : IGFBP-2 | 40 (10–202) | 14 (5–28)*** | 19 (7–89)** |
Molar ratio IGF-2 : IGFBP-3 | 1,4 (0,8-5,1) | 1,6 (0,6-2,2) | 1,2 (0,9-1,8) |
TGF-β (ng/ml) | 11 (3–21) | 11 (5–22) | 9 (4–17) |
KL-6 (ng/ml) | 262 (83–596) | 1050 (314–4951)*** | 889 (359–6168)*** |